Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Regulators, Police Intensify Investigation Of Vaccine Producer For Possible Malfeasance, Cover-up

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Leading Chinese drug maker Simcere Pharmaceutical has revealed that certain personnel at recently acquired vaccine producer Jiangsu Yanshen Biological Technology are under investigation for possible attempts to cover up lapses in good manufacturing practice standards that led to the release of substandard rabies vaccine doses in 2008

You may also be interested in...



Investigators Deepen Criminal Probe Into Chinese Vaccine Producer; Regulators Revoke Production License For Rabies Inoculation

BEIJING - Executives at leading Chinese drug maker Simcere Pharmaceutical disclosed that regulators have revoked the production license for a rabies vaccine made by recently acquired Jiangsu Yanshen Biological Technology

Investigators Deepen Criminal Probe Into Chinese Vaccine Producer; Regulators Revoke Production License For Rabies Inoculation

BEIJING - Executives at leading Chinese drug maker Simcere Pharmaceutical disclosed that regulators have revoked the production license for a rabies vaccine made by recently acquired Jiangsu Yanshen Biological Technology

China's Simcere Pharmaceutical Becomes Beacon For Disclosing GMP Problems At New Vaccine Subsidiary

BEIJING - Just weeks after acquiring a controlling equity stake in vaccine developer Jiangsu Yanshen, leading Chinese drug maker Simcere Pharmaceutical is pressing its new subsidiary to freeze production and replace two top executives that may have been responsible for lapses in good manufacturing practice standards at the vaccine facility

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel